glp 1 discontinuation Causes and consequences of of GLP1RAs or tirzepatide Adding a GLP-1 receptor agonist

Ageing as a risk factor for neurodegenerative disease

Cys residues have nucleophilic thiol side chains that are susceptible to oxidative modifications and are hence amongst the most reactive amino acids

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)

doi:.10.1684/ejd.2018.3494 thoroughly reviews the different dosages of oral tranexamic acid on melasma

Short-term protocols (1216 weeks) at standard doses carry minimal toxicity risk, but long-term use beyond 6 months lacks human safety data as of 2026

Injecting through clothing or without alcohol prep